Clinical trial
A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid…
NCT00462761 · Daiichi Sankyo, Industry · Completed
Key facts
| NCT number | NCT00462761 |
|---|---|
| Title | A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status |
| Official title | Phase I Open-Label, Sequential Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AC220 When Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia |
| Lead sponsor | Daiichi Sankyo, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Acute Myeloid Leukemia, Leukemia, Myelodysplastic Syndrome, AML, MDS |
| Intervention type | Drug |
| Interventions | AC220 |
| Enrollment | 76 |
| Start date | Jan 1, 2007 |
| Primary completion | Mar 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Apr 19, 2007 |
| Last update posted | May 11, 2020 |
| Countries | Georgia, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: